NeoRx: Irrigation required

NeoRx Corp. believes that it already has taken steps to rectify problems that led to suspension last week of a Phase III trial of its skeletal targeted radiotherapy (STR) after severe side effects were detected months after treatment in a Phase I/II trial in multiple myeloma.

In particular, NERX hopes that limiting the

Read the full 527 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers